A Latin American Perspective on the New ACC/AHA Clinical Guidelines for Managing Atherosclerotic Cardiovascular Disease | springermedizin.de

Springer Medizin

nach oben

Current Atherosclerosis Reports

Erschienen in:

01.04.2014 | 2013 Cholesterol Treatment Guidelines (AM Gotto, Section Editor)

A Latin American Perspective on the New ACC/AHA Clinical Guidelines for Managing Atherosclerotic Cardiovascular Disease

verfasst von: Ada Cuevas, Antonio Arteaga, Attilio Rigotti

Erschienen in: Current Atherosclerosis Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Atherosclerotic heart disease and stroke are leading causes of disability and death worldwide, affecting not only developed countries, but also low- and middle-income regions. Different strategies for handling dyslipidemia as a critical pathogenic risk factor for atherosclerosis have been proposed. However, these recommendations are not applied at all in many countries or even in whole regions of the world. Recently, new US guidelines on risk assessment, lifestyle changes, and high blood cholesterol level treatment to manage atherosclerotic disease were released. In this article, we analyze these new guidelines and discuss their potential applications in preventive cardiovascular medicine in Latin America.

Anzeige

1.

World Health Organization. Word health statistics. http://www.who.int/gho/publications/world_health_statistics (2014).

2.

Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, Silva Ayçaguer LC, et al. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am J Med. 2008;121(1):58–65.PubMedCrossRef

3.••

Miranda JJ, Herrera VM, Chirinos JA, Gómez LF, Perel P, Pichardo R, et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS One. 2013;8(1):e54056. On the basis of population-based surveys, this study reports that major cardiovascular risk factors are highly prevalent in Latin America.PubMedCentralPubMedCrossRef

4.

Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation. 2007;115(9):1067–74.PubMedCrossRef

5.

Vinueza R, Boissonnet CP, Acevedo M, Uriza F, Benitez FJ, Silva H, et al. Dyslipidemia in seven Latin American cities: CARMELA study. Prev Med. 2010;50(3):106–11.PubMedCrossRef

6.

Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez Pérez FJ, Rull JA, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42(8):1298–307.PubMed

7.

EPI. Resultados Encuesta Nacional de Salud 2009 – 2010. Available from: http://epi.minsal.cl/estudios-y-encuestas-poblacionales/encuestas-poblacionales/encuesta-nacional-de-salud/resultados-ens (2012).

8.

Tejero ME. Cardiovascular disease in Latin American women. Nutr Metab Cardiovasc Dis. 2010;20(6):405–11.PubMedCrossRef

9.

Margozzini P, Rigotti A, Ferreccio C, Quezada N, Garrido M, Valdés G. Hypertension and the cardiometabolic syndrome in Chile: a review of concepts and consequences for the developing world. Ther Adv Cardiovasc Dis. 2007;1(1):83–90.PubMedCrossRef

10.

Valenzuela AA, Maíz A, Margozzini P, Ferreccio C, Rigotti A, Olea R, et al. Prevalence of metabolic syndrome among Chilean adults. Rev Med Chil. 2010;138(6):707–14.PubMedCrossRef

11.

Cuevas A, Alvarez V, Carrasco F. Epidemic of metabolic syndrome in Latin America. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):134–8.PubMedCrossRef

12.

Lerman-Garber I, Villa AR, Caballero E. Diabetes and cardiovascular disease: is there a true Hispanic paradox? Rev Investig Clin. 2004;56(3):282–96.

13.•

Cortes-Bergoderi M, Goel K, Murad MH, Allison T, Somers VK, Erwin PJ, et al. Cardiovascular mortality in Hispanics compared to non-Hispanic whites: a systematic review and meta-analysis of the Hispanic paradox. Eur J Intern Med. 2013;24(8):791–9. A meta-analysis of the Hispanic paradox base on cohort studies comparing cardiovascular mortality mortality between Hispanic and non Hispanic white populations in U.S.

14.

LaRosa JC, Gotto Jr AM. Past, present, and future standards for management of dyslipidemia. Am J Med. 2004;116(Suppl 6A):3S–8S.PubMedCrossRef

15.

Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005;96(4A):53E–9E.PubMedCrossRef

16.••

Goff Jr DC, Lloyd-Jones DM, Bennett G, O'Donnell CJ, Coady S, Robinson J, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.11.005. This article offers a new approach to risk cardiovascular assessment According to the Expert Panel of the ACC/AHA.

17.••

Eckel RH, Jakicic JM, Ard JD, Miller NH, Hubbard VS, Nonas CA, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.11.003. This article provides updates to dietary and physical activity recommendations for adult patients with high LDL-C and/or hypertension (AHA/ACC guidelines).

18.••

Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.1016/j.jacc.2013.11.002. Long-awaited U.S. guidelines on risk assessment, lifestyle modification and high blood cholesterol treatment to manage atherosclerotic cardiovascular disease.

19.

Valluri S, Gaziano TA. Progress in national and regional guidelines development and deployment for the clinical prevention and control of CVD and diabetes in Africa. Prog Cardiovasc Dis. 2013;56(3):336–43.PubMedCrossRef

20.

Santos RD, Lorenzatti AJ, Barros CF, Escobar E. Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. J Clin Lipidol. 2011;5(3):124–32. doi:10.1016/j.jacl.2011.02.006.PubMedCrossRef

21.••

International Atherosclerosis Society. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. International Atherosclerosis Society. 2013. http://www.athero.org/download/IASPPGuidelines_FullReport_2.pdf. This is a proposal by the IAS for the management of dyslipidemia as a key cardiovascular risk factor.

22.•

Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762–5. A critical analysis of the new U.S. recommendations for prevention of atherosclerotic cardiovascular disease.

23.

Cortes-Bergoderi M, Thomas RJ, Albuquerque FN, Batsis JA, Burdiat G, Perez-Terzic C, et al. Validity of cardiovascular risk prediction models in Latin America and among Hispanics in the United States of America: a systematic review. Rev Panam Salud Publica. 2012;32(2):131–9.PubMedCrossRef

24.

Olivos C, Valenzuela A, Arteaga A, Margozzini P, Olea R, Maiz A, et al. Cardiovascular risk, cholesterol goal attainment, and lipid-lowering eligibility in Chile. Findings from the first national health survey. Atheroscler Suppl. 2007;8(1):121–2.CrossRef

25.

Icaza G, Núñez L, Marrugat J, Mujica V, Escobar MC, Jiménez AL, et al. Estimation of coronary heart disease risk in Chilean subjects based on adapted Framingham equations. Rev Med Chil. 2009;137(10):1273–82.PubMed

26.

Rubinstein AL, Irazola VE, Poggio R, Bazzano L, Calandrelli M, Lanas Zanetti FT, et al. Detection and follow-up of cardiovascular disease and risk factors in the southern cone of Latin America: the CESCAS I study. BMJ Open. 2011;1(1):e000126.PubMedCentralPubMedCrossRef

27.

Aquino EM, Barreto SM, Bensenor IM, Carvalho MS, Chor D, Duncan BB, et al. Brazilian Longitudinal study of adult health (ELSA-Brasil): objectives and design. Am J Epidemiol. 2012;175(4):315–24.PubMedCrossRef

28.•

de Lorgeril M. Mediterranean diet and cardiovascular disease: historical perspective and latest evidence. Curr Atheroscler Rep. 2013. doi:10.1007/s11883-013-0370-4. An updated evidence-based review on the benefits of the Mediterranean diet on cardiovascular disease.

29.

Bermudez O, Tucker K. Trends in dietary patterns of Latin American populations. Cad Saude Publica. 2003;19(Supp 1):S87–99.PubMedCrossRef

30.

Cuevas A, Alvarez V, Olivos C. The emerging obesity problem in Latin America. Expert Rev Cardiovasc Ther. 2009;7(3):281–8.PubMedCrossRef

31.

Uauy R, Albala C, Kain J. Obesity trends in Latin America: transition from under to over nutrition. J Nutr. 2001;131(3):S893–9.

32.

Aschner P, Ruiz A, Balkau B, Massien C, Haffner SM. Association of abdominal adiposity with diabetes and cardiovascular disease in Latin America. J Clin Hypertens (Greenwich). 2009;11(12):769–74.CrossRef

33.

Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059–62.PubMedCrossRef

34.

Rocha AP, Carvalho LC, Sousa MA, Madeira SV, Sousa POJ, Tano T, et al. Endothelium dependent vasodilator effect of Euterpe oleracea Mart. Acaí extracts in mesenteric vascular bed of the rat. Vasc Pharmacol. 2007;46:97–104.CrossRef

35.

Ruiz A, Hermosín-Gutiérrez I, Mardones C, Vergara C, Herlitz E, Vega M, et al. Polyphenols and antioxidant activity of calafate (Berberis microphylla ) fruits and other native berries from southern Chile. J Agric Food Chem. 2010;58(10):6081–9.PubMedCrossRef

36.

Olavarria S, Zacarias I. Barriers and facilitators to increase consumption of fruits and vegetables in six countries in Latin America. Arch Latinoam Nutr. 2011;61(2):154–62.PubMed

37.

Garmendia ML, Corvalan C, Uauy R. Addressing malnutrition while avoiding obesity: minding the balance. Eur J Clin Nutr. 2013;67(5):513–7.PubMedCrossRef

38.

Champagne BM, Sebrié EM, Schargrodsky H, Pramparo P, Boissonet C, Wilson E. Tobacco smoking in seven Latin America cities. The CARMELA study. Tob Control. 2010;19(6):457–62.PubMedCentralPubMedCrossRef

39.

Rojas R, Aguilar-Salinas CA, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, et al. Applicability of the National Cholesterol Education Program III (NCEP-III) guidelines for treatment of dyslipidemia in a non-Caucasian population: a Mexican nation-wide survey. Rev Investig Clin. 2005;57(1):28–37.

40.

Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Chiang CW, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis. 2012;224(1):150–3.PubMedCrossRef

41.

Tonelli M, Wanner C. Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med. 2013. doi:10.7326/M13-2453.PubMed

42.

Psaty BM, Weiss NS. ACC/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence. JAMA. 2013. doi:10.1001/jama.2013.284203.

43.•

Ioannidis JP. More than a billion people taking statins?: potential implications of the new cardiovascular guidelines. JAMA. 2013. doi:10.1001/jama.2013.284657. Two critical appraisals on the applications and implications of the new U.S. cardiovascular guidelines.

44.

Tolonen H, Keil U, Ferrario M, Evans A. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA project. Int J Epidemiol. 2005;34:181–92.PubMedCrossRef

45.••

Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231–43. This multinational prospective survey indicates a very limited use of statins for cardiovascular prevention in low- and middle-income countries.

46.

Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet. 2007;370(9604):2054–62.PubMedCrossRef

47.

Bautista LE, Vera-Cala LM, Ferrante D, Herrera VM, Miranda JJ, Pichardo R, et al. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Aff (Millwood). 2013;32(1):155–64.CrossRef

48.

Valdivieso V, Rigotti A. Health research in Latin America. Lancet. 2010;375(9709):120–1.PubMedCrossRef

Titel: A Latin American Perspective on the New ACC/AHA Clinical Guidelines for Managing Atherosclerotic Cardiovascular Disease
verfasst von: Ada Cuevas
Antonio Arteaga
Attilio Rigotti
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 4/2014
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-014-0400-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Anzeige

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen